1d
Zacks.com on MSNHere is Why Growth Investors Should Buy Cencora (COR) NowGrowth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
But he said to me, ‘My grace is sufficient for you, for my power is made perfect in weakness.’ Therefore I will boast all the ...
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. Learn more on COR stock here.
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...
Kickapoo and Logan-Rogersville girls basketball will represent the Springfield area in this week's MSHSAA Show-Me Showdown in ...
Revenues totaled $81.49 billion, up 12.8% year ... down 2.9% on a reported basis but up 3.3% at cc. The reported decline was due to lower operating income at COR’s global specialty logistics ...
David was too sick to his stomach to eat and slept on the ground in mourning clothes when Nathan the prophet confronted him ...
This morning’s Ivy League Tournament Final features the Yale Bulldogs facing off against the Cornell Big Red to start what ...
12d
Zacks Investment Research on MSNWhy Is Cencora (COR) Up 3.1% Since Last Earnings Report?It has been about a month since the last earnings report for Cencora (COR). Shares have added about 3.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results